Innovation in Addiction Treatment: Where the Field Is Going

Guest host Philip Rutherford and John Driscoll, president and CEO of Caron Treatment Centers, discuss evidence-based addiction treatment, the role of brain health, and emerging innovations like GLP-1 medications and AI-assisted care. What does the future of addiction treatment look like? In this episode, guest host Philip Rutherford sits down with Caron Treatment Centers President and CEO John Driscoll to explore how addiction care is evolving through brain-based science, objective outcome measures and emerging innovations. They discuss everything from GLP-1 medications and AI-assisted care to gambling addiction and the ongoing fight against stigma — while making the case for treating substance use disorder like any other chronic health condition. Objective measures of brain health may improve outcomes, reimbursement and clinical decision-making. Emerging innovations include GLP-1 medications, AI-assisted care, precision medicine and neurological assessment tools. Prevention and early intervention could be the next frontier for behavioral health. John Driscoll is president and CEO of Caron Treatment Centers. He currently serves on the board of directors of the National Association of Addiction Treatment Providers and has over 30 years of experience in the addiction treatment field.   Follow for weekly conversations shaping mental health and substance use care.